scPharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
14/05/2024 22:22
* scPharmaceuticals Inc SCPH.OQ reported a quarterly
adjusted
loss of 36 cents per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of -30 cents. The mean expectation of six analysts for the
quarter was for a loss of 44 cents per share. Wall Street
expected results to range from -51 cents to -39 cents per share.
* Revenue rose 195.8% to $6.10 million from a year ago;
analysts
expected $5.98 million.
* scPharmaceuticals Inc's reported EPS for the quarter was a
loss
of 36 cents.
* The company reported a quarterly loss of $14.11 million.
* scPharmaceuticals Inc shares had fallen by 13.3% this
quarter and lost 30.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 16.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for scPharmaceuticals
Inc is $19.00
This summary was machine generated from LSEG data May 14 at
09:22 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.44 -0.36 Beat
Dec. 31 2023 -0.42 -0.35 Beat
Sep. 30 2023 -0.36 -0.41 Missed
Jun. 30 2023 -0.37 -0.36 Beat